Thalidomide and Analogs as Anti-Inflammatory and Immunomodulator Drug Candidates

Title: Thalidomide and Analogs as Anti-Inflammatory and Immunomodulator Drug Candidates

Volume: 5 Issue: 1

Author(s): Lidia M. Lima, Carlos A. Manssour Fraga, Vera L. Goncalves Koatz and Eliezer J. Barreiro

Affiliation:

Keywords: CYP450, Teratogenicity, bioactivation, thiothalidomide analogs, CoMFA, cAMP

Abstract: Thalidomide ([2-(2,6-dioxo-hexahydro-3-(R,S)-pyridinyl)-1,3-isoindolinedione]), well known by its teratogenic effect, caused birth defects in up to 12,000 children in the 1960s. More recently, this drug was approved by the US Food and Drug Administration for the treatment of erythema nodosum leprosum, under restricted-use program, and a variety of new possible therapeutic applications have been described. This article will accomplish a review of medicinal chemistry aspects of thalidomide and state of the art in the development of new anti-inflammatory and immunomodulator drug candidates designed using thalidomide as lead-compound.

Cite this article as:

Lima M. Lidia, Manssour Fraga A. Carlos, Goncalves Koatz L. Vera and Barreiro J. Eliezer, Thalidomide and Analogs as Anti-Inflammatory and Immunomodulator Drug Candidates, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2006; 5 (1) . https://dx.doi.org/10.2174/187152306775537328